New concepts in pharmacological efficacy at 7TM receptors: IUPHAR Review 2: Developing concepts for drug efficacy by Kenakin, Terry








Department of Pharmacology, University of North Carolina School of Medicine, Chapel Hill, NC,
USA
Dr Terry Kenakin, University of
North Carolina, Pharmacology,
Chapel Hill, North Carolina,
United States, Phone:













The present-day concept of drug efficacy has changed completely from its original
description as the property of agonists that causes tissue activation. The ability to
visualize the multiple behaviours of seven transmembrane receptors has shown that
drugs can have many efficacies and also that the transduction of drug stimulus to
various cellular stimulus–response cascades can be biased towards some but not all
pathways. This latter effect leads to agonist ‘functional selectivity’, which can be
favourable for the improvement of agonist therapeutics. However, in addition,
biased agonist potency becomes cell type dependent with the loss of the
monotonic behaviour of stimulus–response mechanisms, leading to potential
problems in agonist quantification. This has an extremely important effect on the
discovery process for new agonists since it now cannot be assumed that a given
screening or lead optimization assay will correctly predict therapeutic behaviour.
This review discusses these ideas and how new approaches to quantifying agonist
effect may be used to circumvent the cell type dependence of agonism. This article,
written by a corresponding member of the International Union of Basic and Clinical
Pharmacology Committee on Receptor Nomenclature and Drug Classification
(NC-IUPHAR), reviews our current understanding of the interaction of ligands with
seven transmembrane receptors. Further information on these pharmacological
concepts is being incorporated into the IUPHAR/BPS database
GuideToPharmacology.org.
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‘The distinction between affinity and intrinsic activity
therefore seems of general importance . . .’
EJ Ariens, 1954
Historical view of efficacy
Arguably, drugs are defined by three types of properties: their
affinity for the biological target (receptor), their ability to
bind for a period of time sufficient to affect target behaviour
(dissociation rate, target coverage) and their ability to change
target behaviour. This latter term defines the essence of what
drugs do and what will be discussed in this paper as efficacy.
The concept of ‘efficacy’ has evolved over the years; as a
preface to a discussion of present ideas describing efficacy, it
is useful to summarize the changes.
a. Efficacy (intrinsic activity) is system-dependent: Nearly 75
years ago, AJ Clark pointed out the need to differentiate ‘the
capacity to bind and the capacity to excite’ (Clark, 1937).
This was put on a more formal footing 17 years later by EJ
Ariens, who described an ‘effect per unit of pharmacon-
receptor complex’ as intrinsic activity with a scale from
zero (no visible agonism) to one (full tissue agonism)
(Ariens, 1954). Molecules that produced a fractional intrin-
sic activity were classified as partial agonists within this
system of nomenclature. This idea has obvious enormous
importance, but it necessarily links the drug property of
‘efficacy’ with the particular system used to observe it; for
example, while the a-adrenoceptor agonist norepinephrine
is a full agonist in both rat annoccocygeus muscle and vas
deferens, oxymetazoline is a full agonist in the first system
and a partial agonist in the second (Kenakin, 1984). This
limits the scale of intrinsic activity as a descriptor of drugs,
a fact that was pointed by Ariens in his original publication.
Specifically, he stated that intrinsic activity is useful as a
molecular description of agonism only in the special cases
where receptor occupancy is linearly related to drug
response (a limited situation). Of course, for full agonists
(and many partial agonists), this condition does not hold,
so intrinsic activity is limited as a descriptor of agonism to
values within a defined organ system.
Near the same time frame, another treatment of agonism
was given by RP Stephenson, who reported the results of
experiments with a series of closely related alkyltrimethylam-
monium compounds as agonists in guinea pig ileum
(Stephenson, 1956). Specifically, he noted that compounds of
essentially equal potency produced different functional
maximal responses. This indicated to him that there was a
property that differentiated them as agonists beyond affinity
for the receptor; he named the property efficacy. An impor-
tant part of Stephenson’s thesis was that the relationship
between receptor occupancy and tissue response need not be
linear. This important idea defined ‘spare receptor capacity’ as
the ability of agonists to produce maximal tissue response
through occupancy of only fractions of the available receptor
population in a system. This was confirmed in experimental
systems such as guinea pig ileum for histamine through
alkylation experiments with b-haloalkylamines (Nickerson,
1956). Stephenson’s efficacy still was inexorably linked to the
tissue where it is measured; Furchgott (1966) refined the idea
somewhat to ‘intrinsic efficacy’, which defined a unit per
receptor as a scale for efficacy. However, this too is linked to
the particular tissue in which it is measured. An important
distinction between intrinsic activity and efficacy (and intrin-
sic efficacy) is the fact that ratios of efficacies cancel the
tissue-related effects on efficacy (providing that the estimates
are made in the same system under the same conditions).
This provided a powerful tool (namely agonist potency ratios)
for receptor and agonist classification that has been invalu-
able in pharmacology over the past 50 years.
In addition to the fact that it is related to system sensi-
tivity, there are two important concepts relating to Stephen-
son’s efficacy that are relevant to this present discussion. The
first relates to the link between what pharmacologists define
as efficacy and the nature of the assay used to measure
agonism. The Merriam-Webster dictionary defines efficacy as
‘the power to produce an effect’; this associates the property
with the ability to see it. This linking of efficacy with
observed effect dominates pharmacology since the efficacy of
a given drug is defined only by the ability of an assay to
demonstrate an effect. With passing years, the complexity of
the term efficacy has increased in parallel with the ability to
observe complex receptor behaviours. In Stephenson’s world,
there were limited eyes to see receptor activation, in his case
guinea pig ileal contraction. Presently, pharmacologists have
a variety of ways to view receptor activation and the resulting
sequelae of events; these multiple eyes to see have revolu-
tionized pharmacological definitions of efficacy as will be
discussed later in this paper.
The second important concept relates to the use of ratios
of efficacy (or agonist potency ratios) as system-independent
measures of the relative power of agonists to induce a
response. This is only true when the stimulus–response
mechanism linking receptor activation to tissue response is
monotonic; that is, there is only one y value for every value
of x. If this condition is not met, then potency ratios lose
their system independence, and they cannot be used to clas-
sify agonists. This actually has become increasingly impor-
tant in the quantification of biased agonist effects (where
stimulus–response functions may not be monotonic) and
will be dealt with later in this paper.
b. Efficacy is linked to physiology: Mathematically, efficacy
was a somewhat arbitrary proportionality factor intro-
duced to reconcile differences between observed potencies
of agonists and the concentrations binding to the receptor.
Sixteen years after the concept was addressed by Stephen-
son, the arbitrary nature of the concept was reduced by the
expression of agonism in the Black/Leff operational model
of receptor function (Black and Leff, 1983). Specifically,
this model treats the tissue as a virtual Michaelis–Menten
enzyme system and gives a more physiological basis to
agonism. The descriptor of efficacy in this model is the
term t, which embodies the intrinsic power of a molecule
to induce response and also the sensitivity of the tissue as
it converts this power to observed cellular effect. From this
standpoint, t is still linked to the tissue, but as with
Stephenson’s and Furchgott’s efficacy, ratios of t values
become extremely valuable parameters that can be used to
predict agonism in therapeutic systems from measure-
ments made in test systems. However, as with efficacy, for
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ratios of t values obtained from whole cell response to be
truly system independent, there still must be a monotonic
stimulus–response function relating receptor activation to
cell response. Unlike efficacy ratios obtained from whole
cell response, the Black/Leff model describes potential
ways around this requirement when dealing with biased
agonists (vide infra).
c. Efficacy becomes vectorial (inverse agonism). Twenty-three
years after Stephenson defined efficacy, Costa and Herz
(1989) demonstrated its vectorial nature. Although ligands
had previously been shown to depress spontaneously
elevated activity in systems containing benzodiazepine
receptors, the paper by Costa and Herz (1989) was the first
to describe seven transmembrane receptor (7TMR) consti-
tutive activity and the reduction thereof by a ligand. In
particular, the reduction of elevated basal d-opioid receptor
mediated GTP-ase activity in NG108-15 neuroblastoma-
glioma cells by ICI174864 ([N,N′-diallyl-Tyr1, Aib2,3]
Leu5enkephalin) and the demonstration that this ‘inverse’
agonism was blocked by the antagonist MR2266 (2,6-
methano-3-benzazocin-8-ol, 1,2,3,4,5,6-hexahydro-6,11-
diethyl-3(3-furanylmethyl) HCl) with exactly the same
pKB as normal DADLE (D-Ala2,D-Leu5]encephalin)-induced
agonism, elegantly revealed the secret life of 7TMRs as
spontaneously activated beings. In addition to inspiring
Tommaso Costa to introduce a mandatory revision of the
ternary complex model (Samama et al., 1993), the linking
of the effect to a ligand-induced observable response clearly
showed efficacy to be vectorial; that is, as well as being
positive for cell activation, it could be negative. By impli-
cation, previous literature viewed efficacy as excitatory
since it was observed as a change of apparently quiescently
behaviour of cellular systems. With the discovery of inverse
agonism and the realization that receptors could form an
activated state spontaneously came a re-definition of effi-
cacy as the property of a drug molecule that causes a
receptor to change its behaviour towards the cell.
This will be discussed in terms of the molecular mechanism
of 7TMR efficacy further in this paper.
d. Efficacy becomes pluridimensional: With advances in assay
technology came the demonstration that 7TM receptors are
pleiotropic with respect to the number of cellular elements
with which they can interact (e.g. multiple G-proteins;
Prather et al., 1994; 2000; Offermanns et al., 1994; Guder-
mann et al., 1996; Wise et al., 1999; reviewed in Hermans,
2003). Furthermore, improvements in assay technology
(i.e. imaging, dynamic mass distribution, electrical imped-
ance, GTP-ase activity, b-arrestin recruitment, receptor
internalization, ERK activation, receptor phosphorylation,
etc) have provided a plethora of views of 7TM receptor
behaviour in cells beyond simple changes in cellular activ-
ity (Kenakin, 2009a). This revolution has provided a sur-
prising texture in what pharmacologists call efficacy. For
example, before 7TM receptor internalization could be
viewed directly with imaging, it was necessarily linked to
the desensitization and waning of ligand-induced cellular
response. This being the case, the efficacy for receptor
internalization was tacitly assumed to mirror the efficacy to
produce response. This was resoundingly refuted by data
showing that antagonists can induce receptor internaliza-
tion without producing cellular activation (Roettger et al.,
1997; Gray and Roth, 2001). Thus, two types of efficacy
(one for cellular agonism and one for 7TM receptor inter-
nalization) were shown to diverge. A number of other
efficacies followed suit with the uncovering of ligand bias
and functional selectivity (vide infra), leading to the notion
that efficacy is essentially defined by the pharmacological
eyes we have to see it. Seen in this light, ligands could have
a number of efficacies (depending on the response being
monitored), a phenomenon succinctly described by Galan-
drin and Bouvier as ‘pluridimensional efficacy’ (Galandrin
and Bouvier, 2006).
e. Potency ratios show variability: The concept of a monot-
onic function linking agonist receptor occupancy and cel-
lular response was enormously valuable to drug discovery
since it allowed the quantification of test agonist activity in
a system-independent manner. However, over the past 25
years, reports have emerged to question the simple rela-
tionship between occupancy and response predicted by
monotonic efficacy systems (Roth and Chuang, 1987;
Mottola et al., 1991; Roerig et al., 1992; Fisher et al., 1993;
Gurwitz et al., 1994; Lawler et al., 1994; 1999; Ward et al.,
1995; Heldman et al., 1996; Mailman et al., 1998). Some
notable examples of data that clearly are incompatible
with the predictions of the then current receptor theory
were reported for dopamine (Mailman et al., 1998; Mottola
et al., 2002) and serotonin (Berg et al., 1998). The earliest
mechanism proposed for this variability was the idea that
agonists stabilize different receptor conformations, and
that these go on to differentially activate cellular signalling
pathways (Kenakin, 1995a). This concept was termed
‘stimulus trafficking’ and was postulated as a mechanism
for agonist bias in functional systems. Under these circum-
stances, the minimal pharmacological unit for agonism is
the agonist-bound receptor active state and not the recep-
tor per se. An active state-based response system necessarily
predicts that different agonists can bias their signalling to
the cell in different ways; these ideas have been discussed
in numerous reviews (vide infra) and will be considered in
more detail in this paper as it pertains to the definition of
pharmacological efficacy. At the least, the data published
in the 1980s and 1990s compelled a more complex view of
efficacy than it being a proportionality factor linking
agonist receptor occupancy and cellular response.
At present, efficacy can be considered vectorial and ligand
dependent. In addition, a number of ‘efficacies’ can be asso-
ciated with antagonists and other molecules that do not
necessarily activate signalling pathways in cells. These data
strengthen counter-arguments to the historical view that
only agonists possess efficacy and alternatively suggests that
all ligands with affinity also have efficacy (see discussion vide
infra). This takes us to the present state of understanding of
the phenomenon of efficacy as a general property of (all)
drugs. To discuss further refinements of efficacy, it is useful to
consider its molecular mechanism within the context of 7TM
receptor function.
Molecular mechanisms of efficacy
Implicit in pharmacological models of receptor function is
the idea that agonist binding leads to changes in the receptor
BJP T Kenakin
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that, in turn, cause the cell to respond. Seven transmembrane
receptors are allosteric proteins designed to transmit informa-
tion through changes in tertiary conformation; thus, it is
logical to assume that the change in the receptor produced by
the agonist is a change in tertiary conformation. If that con-
formation triggers cellular response or a change in the behav-
iour of the protein towards the cell, it is generally referred to
as an ‘active state’. Two opposing mechanisms proposed
on theoretical grounds to account for this process are
‘conformational induction’ (whereby the ligand causes a
deformation of the protein to a new conformation) and ‘con-
formational selection’ (whereby the ligand selectively stabi-
lizes one of, at least, two pre-existing conformations that are
in equilibrium with each other) (Burgen, 1981).
The idea that a molecule alters the conformation of the
protein to suit its nature is intuitively attractive and in
keeping with Koshland’s original concept of ‘induced fit’; as
put by Koshland: ‘The substrate may cause an appreciable
change in the three-dimensional relationship of the amino
acids at the active site’ (Koshland, 1958). The concepts of
induction and selection are two expressions of the same
molecular mechanism of protein conformational change (see
Figure 1). However, support for conformational selection
comes from considerations of the high levels of energy
required to cause a protein to adopt a conformation that is
not present in its native library of spontaneously formed
conformations. Selection is also supported by kinetic features
of the production of receptor active states that are required
for cellular function. Considering the scheme in Figure 1, the
time course of ligand-induced receptor active state produc-
tion is given by the integration of the differential equations
d[AR]/dt = k1[A][R] - k-1[AR] and d[AR*]/dt = k2[AR] – k-2[AR*]
(Bosshard, 2001). Given that the formation of a complex
between the agonist and the inactive receptor complex will
be weak, a reasonable estimate for k1 is 104 M-1 s-1. Consider-
ing values for conformational changes in proteins of 102 s-1
and integration of the differential equations yields a half-time
for the formation of [AR] of 2.5 h (equilibrium would be
reached only after a day). In contrast, utilizing reasonable rate
constants, a mechanism of conformational selection yields a
half-time of approximately 80 s (Bosshard, 2001). Thus, while
conformational induction could lead to agonism, the time
course would be unacceptably long for cellular life. Pharma-
cological evidence also supports conformational selection
with the discovery of spontaneous formation of receptor
active states that are detected by cellular response proteins
(Costa and Herz, 1989). In these systems, a receptor active
state is produced in the absence of ligand, thereby precluding
conformational induction as a mechanism. In general, con-
formational selection furnishes a simple and economical
mechanism of agonism, whereby an agonist preferentially
stabilizes a receptor active state. It should be noted that the
stabilization of a protein conformation that is only rarely
made spontaneously would closely resemble, but not be, con-
formational induction (Kenakin, 1996).
The most parsimonious model of agonism by conforma-
tional selection is to define only two receptor states: one
‘inactive’ in that it does nothing to the cell and one ‘active’
that triggers cellular response. In terms of conformational
selection, agonist efficacy would be defined as the selective
affinity of the agonist for the two receptor states in equilib-
rium with each other as Ri and Ra controlled by an allosteric
constant L.
It can be shown that a differential affinity (defined as the
term a where a  1 in Figure 2A) necessarily will lead to a
change in the system from that present in the absence of the
ligand through the ratio r•/r0 (where r0 is the fraction of
receptors in the Ra state in the absence of ligand, and r• is the
fraction in the presence of a saturating concentration of













Such a system will re-equilibrate according to Le Chate-
lier’s principle towards enrichment of the protein species for
which the ligand has the greater affinity. Thus, if a > 1, the
active state will be enriched, and positive agonism will result.
If a < 1, then the inactive state will be enriched, and inverse
agonism will result. It can be seen that no change in the
relative concentrations of the two states occurs only in the
case where a = 1 (the ligand A has identical affinities for both
states).
The next question is how does the active state cause
cellular response? Several lines of evidence involving the
ternary complex (DeLean et al., 1980) hypothesis for 7TM
receptors support an allosteric mechanism, whereby the
active state of the receptor has an altered reactivity towards a
signalling protein, causing it to further activate signalling
cascades within the cytosol. In this regard, it is useful to
Figure 1
Scheme for binding of a ligand (A) to a receptor (R) that can exist
in two states R and R*. It is assumed that the ligand-directed end-
point is production of the R* state through binding to form AR*. A
mechanism of selection is through a selective binding of A to the
R* state to cause an enrichment of AR*. A mechanism of induction
has A binding to the R state followed by a conformational change
to the R* state.
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consider 7TM receptors as conduits in an allosteric system,
whereby the agonist functions as a modulator and the signal-
ling protein a ‘guest’ (Kenakin and Miller, 2010). Thus,
binding of the modulator causes a change in the conduit to
alter its affinity for the guest. This mechanism is shown
schematically in the extended ternary complex (ETC) model
of 7TM receptors (Samama et al., 1993):
Within this scheme, signalling proteins such as
G-proteins bind to the active state of the receptor (with affin-
ity Kg) and to the agonist-bound active state of the receptor
with another (and presumably enhanced) affinity gKg.
Implicit in this model is the fact that different agonists can
impart a different value of g to the receptor; thus, efficacy
becomes a complex function of both a and g. Under these
circumstances, the ‘two-state’ model shown above for spon-
taneously formed receptor states also functions as a multi-
state model in the presence of agonists (the multi-aspect
coming from ligand specific values of g). It should be noted
that the ETC model also implicitly states that the binding of
the G-protein to the activarted receptor automatically leads
to activation. In view of data to show that non-signalling
ternary complexes with ligands have been detected in some
systems (see Kenakin et al., 2000), a more complete linkage
model of 7TM function is described by the cubic ternary
complex model (CTC model; Weiss et al., 1996a; b; c).
However, for the purposes of this discussion of efficacy, the
distinction between the ETC and CTC model is not relevant.
The ETC model was proposed to describe the most com-
monly measured 7TM receptor response at the time, namely
the activation of G-proteins, but theoretically it applies to the
binding of any signalling protein (i.e. b-arrestin) to the recep-
tor leading to response. The appearance of the ternary ARaG
species in the extended ternary complex model highlights a
key feature of 7TM receptors, namely that they are allostseric
proteins. Before discussing efficacy further, it is useful to
consider this property in describing agonism since allosterism
is particularly noted for probe dependent effects (the allos-
teric effect of a molecule on one receptor probe can be com-
pletely different from its effect on another, vide infra).
Efficacy and the allosteric nature
of 7TMRs
As noted previously, 7TMRs are allosteric proteins. Defining
energy as the interaction of a modulator through a conduit
(receptor protein) to affect that conduit’s interaction with
another molecule (termed the guest) further defines agonism
as an allosteric vector. Agonism is that vector directed towards
Figure 2
7TMR agonism as an allosteric system. (A) Classic guest allosterism whereby the effects of a ligand A are modified by the binding of a modulator B
to a separate site on the receptor. The affinity of A is altered by a factor a upon binding of B; similarly, the efficacy of A is altered by a factor b. The
effects of A are reciprocated on the affinity and efficacy of B. The equation yields the response to the ligand A in terms of the Black/Leff operational
model with A as an agonist of affinity KA-1 and efficacy tA. (B) 7TMR agonism with the agonist as a modulator M and cytosolic signalling protein j
as the allosteric guest. The equation yields response as the Black/Leff fucntion with the receptor/signal protein complex ([jR]) as the agonist species.
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the cytosol with the modulator as agonist and signalling
proteins as guests. Therefore, agonism should follow the same
rules as classical guest allosterism described for allosteric
modulators (such as allosteric antagonists and positive allos-
teric modulator PAMs) (see Figure 2A). The model to describe
the latter type of system is a melding of the Ehlert model for
allosteric interaction of a ligand [A], modulator [B] and recep-
tor (R) (Ehlert, 1988) and the Black/Leff operational model for
functional agonist response (Black and Leff, 1983). The result-
ing model (Ehlert, 2005; Kenakin, 2005; Price et al., 2005)
provides an equation for the effects of any allosteric modulator
on the response produced by an agonist. A concise and con-
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where Em is the maximal response of the system; KA and KB are
the equilibrium dissociation constants of the agonist and
modulator, respectively; n is the Hill coefficient of the dose–
response curve; a is the effect of the modulator on agonist
affinity; b is the effect of the modulator on agonist efficacy;
and tA is the efficacy of the agonist. A redefinition of the
components of the allosteric system leads to an equation of
identical form to describe selective functional agonism (see
Figure 2B). Thus, defining the agonist as modulator [M] and
the guest as a signalling protein denoted j, it can be seen that
the amount of ligand-bound receptor complex to the signal-
ling protein is given by an equation of the same form as
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Within this scheme, unliganded receptors induce pathway
activation through the efficacy parameter t. Equation 3 shows
how biased agonism is the same as the phenomenon of probe
dependence, a well-known property of guest allosterism,
through the properties of a and b. Probe dependence dictates
that the effects of a given modulator can be very different for
different receptor guests (Kenakin and Miller, 2010; Suratman
et al., 2011). For example, the CCR5 HIV allosteric entry
inhibitor aplaviroc reduces the binding of the chemokine
CCL3 to the receptor but does not affect the binding of
another chemokine (CCL5) (Maeda et al., 2004; Watson et al.,
2005). Biased signalling also could furnish a way in which
apparently redundant natural ligands can provide finely tuned
selective signalling. For example, the natural chemokine
CCL19 produces phosphorylation of the chemokine receptor
CCR7 through GRK3 and GRK6; while another natural chem-
okine for this receptor, CCL21, only utilizes GRK6. While both
phosphorylation events lead to b-arrestin-2 recruitment, they
produce different functional consequences in that CCL19, but
not CCL21, produces receptor redistribution of CCR7 receptor
into endocytic vesicles (Zidar et al., 2009).
Any binding ligand theoretically can produce an allosteric
effect on 7TMRs; and this, in turn, can lead to probe depend-
ence. For example, the PAM NOVO2 produces a 25-fold
potentiation of the GLP-1 receptor agonist oxyntomodullin
but only a 1.5-fold potentiation of the agonist GLP-1(7–
36)NH2 (Koole et al., 2010). This is formally identical to
having a biased agonist as the modulator producing a given
effect of the receptor interaction with one guest (i.e.
G-protein) through the parameters a and b, and a completely
different effect on another guest such as b-arrestin (with yet
another set of a and b values). Thus, it can be seen how
agonist efficacy is compatible with allosteric theory describ-
ing effects through the parameters a and b.
One of the most interesting aspects of allosteric modula-
tion of affinity (a) and efficacy (b) is the independence of
these effects. This can lead to advantageous therapeutic prop-
erties. For example, allosteric antagonists that increase the
affinity but decrease the efficacy of natural agonists become
more active with increasing activation of the system; that is,
they get more potent when they need to. This behaviour is
seen with the NMDA receptor antagonist ifenprodil (Kew
et al., 1996) and the cannabinoid receptor antagonist
Org27569 (5-chloro-3-ethyl-1H-indole-2-carbox-ylic acid
[2-(4-piperidin-1-ylphenyl)ethyl]amide) (Price et al., 2005).
Strikingly different effects on agonist efficacy (from positive
to negative through values of b ranging from fractions to >1)
with a uniform increase in affinity have recently been
reported for the muscarinic receptor ligand LY2033298 on
various muscarinic receptor subtypes (Valant et al., 2012).
Not only can allosteric ligands change the quantity of
efficacy of an agonist but also the quality of efficacy. In cases
where receptors mediate pleiotropic signalling (i.e. interact
with multiple signalling proteins such as G-proteins,
b-arrestin, etc.), allosteric changes in receptor conformation
may produce unpredictable changes in the way natural and
synthetic agonists signal through the receptor. For example,
GLP-1 agonists produce increases in cAMP, phosphoERK1/2
and calcium effects through activation of the GLP-1 receptor.
The PAM NOVO2 potentiates cAMP effects but otherwise
does not alter the calcium signalling characteristics of GLP-1
agonists (Koole et al., 2010).
The allosteric nature of 7TMRs opens ideas about screen-
ing for new ligands. Specifically, since guest molecules
control the affinity of modulators, specific signalling path-
ways may be targeted for screening through production of
conduit–guest complexes in screening assays. In this regard,
7TMR screening would be similar to recent strategies for
selective nuclear receptor screening (Norris et al., 2009). At
this point, it is worth considering some practical aspects of
bias signalling as it pertains to defining efficacy and quanti-
fying it for therapeutic advantage.
Molecular dynamics of 7TM receptors
The discussion of g in the ETC model raises the spectre of
possible multiplicity of receptor states (as defined by their
varying affinity for G-proteins). Two-state models economi-
cally described agonism with the least number of assump-
tions until experimental evidence emerged from a number of
types of studies to unequivocally show that receptors can
form numerous ‘active’ states. First, there is direct evidence to
show that agonist-bound receptors yield active states differ-
ent from the natural spontaneously formed constitutive
active states. One of the most striking examples of this is the
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demonstration of ‘protean agonism’ for some ligands. In
these cases, molecules function as positive agonists in quies-
cent (non-constitutive) receptor systems and inverse agonists
in constitutively active systems (Kenakin, 1995b; 2001). The
most simple explanation of this effect is that the ligand sta-
bilizes an active state of lower intrinsic efficacy than the
spontaneously formed consitutive active state. Further exam-
ples of differences between the constitutively active and
ligand-bound b2-adrenoceptor can be observed in the respec-
tive signalling pathways activated by each receptor species.
For example, in a system consisting of TG4 transgenic murine
cardiomyocytes, constitutively activated b2-adrenoceptors
produce elevation of cAMP and no change in the cardiac
L-type Ca2+ current (ICa). In contrast, the agonist zinterol
elevates ICa. These data show that the active states of the
b2-adrenoceptor differ in their signalling characteristics (Zhou
et al., 1999). Similarly, the photolabelling studies of Ga subu-
nits with azidoanilido-[a32P]GTP in GH3 cells has shown that
agonist bound m-opioid receptors ([D-Ala2,N-MePhe4,Gly-
ol5]ekephalin) activate G-proteins differently from constitu-
tively active m-opioid receptors (Liu et al., 2001). In addition,
it has been shown that the constitutively active (agonist-
independent) m-opioid receptor undergoes phosphorylation
at Ser363, but the agonist-activated m-opioid receptor
(DAMGO-bound) undergoes phosphorylation at Thr370 (Doll
et al., 2011; Lau et al., 2011).
There also is a great deal of data to show that different
ligands produce different receptor conformations. The data
can be categorized with the means by which these different
conformations are detected, namely by the cell or through
physicochemical experiments. Since receptors are allosteric
proteins that are probed by cellular signalling proteins from
the cytoplasm, different receptor conformations can be
detected through differences in cellular signalling. While the
therapeutic significance of these actions is still in question,
the effects have been validated in many systems with numer-
ous receptors (see reviews Kenakin, 2002a,b; 2006; 2007;
Hermans, 2003; Kukkonen, 2004; Perez and Karnick, 2005).
Therefore, the fact that biased signalling occurs is consistent
with the stabilization of different 7TMR active states by
ligands as this is the most simple explanation of the effect
(Kenakin, 1995a). These phenomena have been described
under the general term(s) biased agonism and/or functional
selectivity and will specifically be discussed later in this paper
(vide infra).
In addition to cellular readouts of selective receptor con-
formations, various chemical and structural approaches have
demonstrated ligand-specific differences in receptor confor-
mation. Thus, techniques such as fluorescent resonance
energy transfer (Vilardaga et al., 2003; 2005; Swaminath et al.,
2004; 2005; Granier et al., 2007; Lohse et al., 2008; Zurn et al.,
2009), bioluminescence resonance energy transfer (Galandrin
et al., 2008; Lohse et al., 2008), circular dichroism (Baneres
et al., 2005), antibody binding (Tutor et al., 2007), kinetic
studies (Swaminath et al., 2004), fluorescent receptor probes
(Gether et al., 1995; Ghanouni et al., 2001; Kobilka and
Gether, 2002), plasmon waveguide resonance spectroscopy
(Hruby and Tollin, 2007; Georgieva et al., 2008), X-ray crys-
tallography (Okada and Palczewski, 2001), 19F-NMR (Liu et al.,
2012) and site-directed mutagenesis (Pellissier et al., 2009) all
have shown that 7TMRs can form different tertiary confor-
mations upon binding to different ligands. Computational
methods also indicated how numerous receptor conforma-
tions can be formed. For example, ligand-induced rotational
orientation changes in 7TMR helices of the b2-adrenoceptor
demonstrate the production of agonist-selective 7TMR con-
formations. Specifically, the changes produced by agonists
such as norepinephrine and dopamine (breaking of the ionic
lock between R1313.5 and the intracellular end of TM3 and
E2686.30 on TM6) and engagement of the rotamer switch
(toggle switch on W2866.48) are not produced by the agonists
salbutamol (which only breaks the ionic lock) or catechol
(which only engages the rotamer toggle switch) (Bhattach-
arya et al., 2008). In light of the data to show 7TMRs have the
intrinsic ability to form numerous conformations, it is useful
to describe receptor systems in terms of molecular dynamics
and probability functions. This considers proteins as dynamic
systems of interchangeable conformations, the sum of which
is referred to as an ensemble (Onaran and Costa, 1997;
Onaran et al., 2002).
Multiple receptor states can be described with linkage
models by defining additional receptor species that go on to
interact with signalling proteins; for example, a three state
model of receptor signalling has been proposed (Scaramellini
and Leff, 2002). However, a limitation to reconciling newly
obtained data with early descriptions of efficacy is the need to
define and incorporate these new species into equations. In
cases of multiple receptor states, this becomes unwieldy and
requires too many un-verifiable parameters. Molecular
dynamic techniques can be used to estimate the probability
of multiple protein states and can facilitate thinking in terms
of multiple conformation states, efficacies and biased signal-
ling. Probability partition functions have shown that ligand
binding is not a passive process but rather that it actively
modifies the conformational makeup of receptor ensembles
(Onaran and Costa, 1997; Kenakin and Onaran, 2002;
Onaran et al., 2002). A useful view is to envision receptor
proteins as rolling on an ‘energy landscape’ sampling a
number of conformations as low energy wells within this
landscape (Fraunfelder et al., 1988; 1991; Woodward, 1993;
Hilser and Freire, 1997; Freire, 1998; Hilser et al., 1998; 2006;
Ma et al., 2002). As discussed previously and as shown by
equation 1, if a ligand has different affinity for two receptor
states (a  1) and if the states are in reversible equilibrium
with one another, then the presence of the ligand necessar-
ily will change the makeup of the system (relative amounts of
each conformation). This effect is compounded for a receptor
ensemble since there are many more options for the ligand to
choose. For example, the effect of a saturating concentration
of ligand on an ensemble of 1 to n states on the fraction of










































It can be seen from equation 4 that only in the case where
a1 = a2 = a3 = . . . = ai = 1 (the ligand has identical affinity for
all states) will the ratio of states not change upon ligand
binding. Considering that it is unlikely that the ligand will
have identical affinities for a large number of receptor states,
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this suggests that every ligand that binds to a receptor will in
some way also alter the composition of the ensemble that is
presented to the cell. This alteration in the composition of
the receptor ensemble is the manifestation of ligand efficacy.
On theoretical grounds, it has been shown through the appli-
cation of probability partition functions to virtual data that
affinity and efficacy are necessarily correlated (Kenakin and
Onaran, 2002). These ideas further strengthen the notion
that all drugs have affinity and efficacy (and that these
pluridimensional efficacies may need to be observed through
specifically designed assays).This also predicts that if a ligand
binds to a receptor, it necessarily will change the behaviour of
that receptor; that is, it will have some form of efficacy.
The idea that the process of drug binding to a receptor
necessarily will change its conformation to cause a detectable
effect (all drugs may have some form of efficacy) forms the
rationale for generic ligand detection approaches utilizing
bioluminescence resonance energy transfer (BRET) technol-
ogy on separate proteins (Kocan and Pfleger, 2009; 2011),
fusion proteins (Kocan et al., 2011) or dual BRET probes on
receptors (Dacres et al., 2011). The collorary to this idea is
that any ligand that binds to a receptor should be tested in
every possible functional assay for that receptor in order to
detect possibly useful therapeutic activity. For example, it has
been known for a number of years that desipramine binds to
a2-adrenoceptors but produces no overt a2-adrenoceptor
response. However, recently, this binding has been linked to
arrestin recruitment with no concomitant a2-adrenoceptor
signalling. The b-3 arrestin recruitment has been linked to
internalization of the a2-adrenoceptor which may, in turn, be
associated with a useful clinical phenotypic profile in depres-
sive disorders (Cottingham et al., 2011).
In terms of agonist efficacy and cell signalling, the altera-
tion of receptor ensembles is compatible with different ago-
nists producing unique patterns of cellular signalling through
stabilization of sets of receptor conformations. The definition
of a 7TMR active state should be reconsidered in terms of this
idea. Specifically, regions of proteins move independently;
thus, it cannot be assumed that a defined conformation in
one region of the protein will always be formed with another
defined conformation in another region of the protein. For
example, if a given region of the receptor is in a fixed con-
formation, there will be an ensemble of conformations (some
more prevalent than others) associated with that fixed
regional conformation. If a region is fixed through ligand (see
Figure 3A), there will be a selectively stabilized ensemble of
conformations available for binding of guest molecules asso-
ciated with that stabilized conformation (Figure 3B). The sta-
bilization of certain preferred conformations by any given
ligand will define the subsequent conformations of the
cellular (guest) regions of the receptor to affect the confor-
mations of the receptor presented to the cell. Thus, a ligand-
stabilized receptor conformation could mean that a restricted
and enriched ensemble of conformations will be presented to
the cell cytosol to interact with signalling proteins. It would
be unrealistic to assume that two ligands would stabilize
identical proportions of these conformations, suggesting, in
turn, that ligands will have a unique ‘bias’ towards the active
states they present to cellular systems.
It is worth considering the question, how does a given
ligand express a physiological activity through 7TMR confor-
mation stabilization within an ensemble environment?
Given that receptor proteins explore their energy landscape,
at any single instant, a snapshot of the basal ensemble would
show a distribution of various conformations. Within this
distribution would be conformations that lead to a cellular
function (i.e. G-protein activation, b-arrestin binding, phos-
phorylation, etc.). As discussed previously, there would a
distribution around these pharmacologically active confor-
mations due to the fact that amino acid residues move inde-
pendently. Therefore, there would be a small distribution of
conformations around the region relevant to signal protein
binding in other regions of the protein (see Figure 4). As
noted, ligands contribute energy to this system through
binding to selected conformations (Figure 3B). Those ligand-
stabilized conformations that are coincident with pharmaco-
logically active conformations will therefore provide the
ligand with its pharmacological profile (Kenakin, 2002a). It
should be noted that there are no data to indicate that there
would only be one specific active state conformation respon-
sible for the activation of a given signalling pathway but
rather a preferred distribution of pathways. Thus, agonism
would be the interaction of an agonist-stabilized population
of conformations and a preferred population of active states
for a particular signalling pathway. Figure 4 shows three
hypothetical ligands that stabilize various conformations
within the basal ensemble. The conformations coincident
with two pharmacologically relevant ensembles (labelled G1
activation and b-arrestin) also are shown. The prevalence of
these ensembles (either through the quantity that is stabi-
lized and/or time spent in that conformation) defines the
relative propensity of each ligand to produce activation of the
pathway. The relative activation, in turn, makes up each
ligands bias towards those signalling pathways (Figure 4). A
Figure 3
Keeping the conformation of a region of the 7TMR relatively fixed
(through binding of a ligand) will lead to a biased ensemble of
conformations throughout the protein. Insofar as some of those are
associated with coupling to cellular signalling proteins, this will
define the pharmacologic action of the ligand when the receptor is
in the cell membrane. These various signalling regions of the recep-
tor will adopt an ‘active state’ conformation with a range of prob-
abilities depending on the nature of the ligand (histogram in panel
B). Specifically, the frequency of occurrence of any given conforma-
tion will be influenced by the nature of the ligand binding to the
receptor leading to a unique frequency distribution of conformations
associated with that ligand.
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further sophistication of this effect occurs if the guest mol-
ecule itself can form a range of conformations. For instance,
it has been shown that b-arrestin can form a number of active
conformations that can be stabilized by different ligand–
receptor complexes (Shukla et al., 2008).
Efficacy and biased signalling
Agonist bias can be described as the ability of an agonist to
differentially activate some cellular signalling pathways over
others. However, this must be put into context that differen-
tiates system bias from ligand bias. The former idea recognizes
that not all cellular pathways will be coupled equally in any
given cell; that is, the efficiency of coupling of signalling
pathways will be wired according to the specific needs of a
particular cell. For example, cardiac inotropy (increased iso-
metric force of contraction) and lusitropy (rate of relaxation)
are differentially coupled in a guinea pig atrium (Kenakin
et al., 1991) such that dose–response curves to b-adrenoceptor
agonists for lusitropy lie approximately threefold to the left of











































Receptor concormational ensembles as frequency distributions. Top panel shows distributions of the unliganded receptor for a defined instant in
time (lines identify relative quantity of a distribution). Grey distributions define the arrays of conformations that have an identifiable cellular
function (i.e. activation of G-proteins, phosphorylation of receptor protein, etc.). Presence of a conformation coincident with a conformation in
the pharmacologically functional ensemble indicates the basal activity of the system. For the unliganded receptor, few spontaneously formed
conformations produce cellular efect. Middle panels show the effects of the binding of three separate ligands (A, B and C). With ligand binding
comes clustering of conformations coincident with pharmacologically active ensembles. The presence of these pharmacologically active confor-
mations define the observed activity of the ligand. Lower panels show how differences in ligand-stabilized clusters of conformations result in
varying ratios of pharmacological activity for different pathways.
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cellular cAMP to initiate relaxation that it does inotropy in
this particular tissue. This is not a therapeutically useful bias
as it will be unique to the particular system being tested and
cannot be relied upon to be true in humans. In addition, this
system bias will be operative for all agonists. Therefore, the
agonists pirbuterol and isoproterenol both are subject to
system bias but are identical in their ability to produce the
two responses (Kenakin et al., 1991); they demonstrate no
ligand bias. Within system bias, there can be ligand bias if
agonists differ in their propensity to activate pathways
within a given system bias; this reflects the stabilization of
unique receptor conformations and constitutes ligand bias.
These types of effects would be expected to remain with the
agonist–receptor pairs and carry over into a useful therapeutic
bias. Therefore, ligand bias must be expressed relative to a
reference agonist in any given system. It could be argued that
the natural agonist would be a good choice, since differences
seen for a synthetic agonist would then predict possible dif-
ferences from endogenous signalling.
The foregoing discussions have shown how cytosol-
directed allosteric probe dependence can lead to selective
activation of signalling pathways by agonists; this topic has
been reviewed recently in a number of publications (Perez and
Karnick, 2005; Leach et al., 2007; Mailman, 2007; Kenakin
and Miller, 2010). It is worth considering the positive and
negative aspects of these phenomena. On the positive side,
biased ligands have the potential to be better therapeutic
entities than unbiased ligands (Maudsley et al., 2005; DeWire
and Violin, 2011). For example, two major 7TMR pathways
are G-protein activation and b-arrestin binding. Insofar as
b-arrestin-2 binding is known to be a switch to turn off
G-protein signalling, ligands biased to not recruit b-arrestin
would be proposed to yield more persistent G-protein-based
signalling and less desensitization (i.e. opioid receptor anal-
gesia, Varga et al., 2004; Raehal et al., 2005; Groer et al., 2007).
On the other hand, long-term low-level b-arrestin-based sig-
nalling has been identified as potentially useful for some
receptors such as the PTH receptor for ligands aimed at treat-
ing osteoporosis (Ferrari et al., 2005; Gesty-Palmer et al.,
2009), angiotensin ligands treating heart failure (Violin and
Lefkowitz, 2007; Violin et al., 2010; Boerrigter et al., 2011) and
GPR109-mediated treatment of displidaemia (Walters et al.,
2009). The possible beneficial effects of b-arrestin signalling in
cardiac function recently have been discussed (Tilley, 2011).
Such unique profiles are not confined to agonists since allos-
teric antagonists and PAMs also have the potential to be
superior therapies through signalling bias (Kenakin, 2010).
While offering possible therapeutic advantage, biased sig-
nalling also raises challenges to new drug discovery and the
quantification of agonism. The fact that some agonists may
stabilize different states of pleiotropically coupled receptors
can lead to the degeneration of the simple monotonic rela-
tionship between agonist receptor occupancy and tissue
response. Specifically, if the total cell response is a composite
of several stimuli (i.e. entry of extracellular calcium plus
release of intracellular calcium stores, ERK activation through
G-protein plus b-arrestin stimulation, etc.), then the relative
stoichiometry between the various signalling elements and
receptors comes into play unless the agonists produce iden-
tical receptor states (as measured by identical activation of
the pleiotropic signalling systems). For example, Figure 5
shows a receptor coupled to two signalling proteins activated
by two agonists A and B. These agonists stabilize different
active states such that agonist A is relatively unbiased towards
effector pools 1 and 2, while agonist B is biased towards
effector pool 2. Such variances in pathway activation are
becoming well known such as the differences in the PTH
receptor agonists [Trp1]PTHrp-1–36 and PTH-1A. Specifically,
[Trp1]PTHrp-1–36 activates ERK mainly through G-protein
pathways whereas the agonist PTH-1A activates ERK mainly
through b-arrestin (Gesty-Palmer et al., 2006). For the
example shown in Figure 5, the relative potency of agonists A
and B may then vary depending on the relative emphasis of
the stimulus coming from effector pools 1 and 2. Thus, the
activity of agonist B will be disproportionately augmented in
cells with a higher relative stoichiometry of effector pool B
(see Figure 5). In this way variations in the availability of
signalling components become a clear potential mechanism
for cell-based variation in agonist efficacy. An example of this
has been reported for 5-HT2A receptor agonists. Specifically, it
has been shown that RSK2 (p90 ribosomal S6 kinase) attenu-
ates 5-HT2A signalling through phosphorylation (Sheffler
et al., 2006; Strachan et al., 2009). Accordingly, some but not
all 5-HT2A agonists demonstrate augmented responses in
RSK2 knockout mouse embryonic fibroblasts paralleling their
relative dependence on this pathway (Strachan et al., 2010).
The relative stoichiometry between receptors and pools of
signalling molecules has been shown to be a factor in vitro
with expression levels of the human calcitonin receptor. Low
expression levels of calcitonin receptor in HEK 293 cells
produce cells that, when activated by calcitonin agonists,
only yield elevations in cAMP; whereas higher expression
levels produce cells responding with elevated cAMP and
calcium levels (Kenakin, 1997). This type of receptor density
effect may even be extended to the special pattern of receptor
expression on the cell surface. Thus, in spatially oriented
intestinal epithelial cells, apical and basolateral proteinase-
activated receptor-2 (PAR-2) receptors function as distinct
pools in terms of receptor signalling (Lau et al., 2010). Cell-
based variance in efficacy have been seen experimentally
with differences in cell type (Table 1A), signal coupling stoi-
chiometry (Table 1B) and assay format (Table 1C). In addi-
tion, cell-based agonist variability is observed in whole cell
phosphorylation patterns. For instance, the muscarinic M3
receptor is differentially phosphorylated in different cell and
tissue types, indicating a role for cell-specific phosphoryla-
tion in cell-specific signalling (Butcher et al., 2011).
As a general rule, the farther from the initial receptor
binding event a signalling cascade is viewed, the more likely
it will have the capability of detecting texture in efficacy. For
example, the angiotensin agonist SII promotes the recruit-
ment of b-arrestin to the angiotensin receptor. However, this
single event can then be shown to promote the global
receptor-mediated phosphorylation of proteins by angi-
otensin receptor activation to yield changes in the phospho-
rylation of 35 proteins (Xiao et al., 2010). It will be interesting
to see if these complex patterns of global phosphorylation
change with stimulation with different agonists.
Increases in the number of agonist-mediated cellular
processes also can yield texture in overall efficacy measure-
ments (i.e. differences between agonists will more likely be
observed). For example, Evans et al. (2010) have shown that
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b-adrenoceptor ligands produce different patterns in the
levels of various intracellular signalling molecules. They
express these with a novel 10-axis graph representing a ‘web
of efficacy’. Consideration of the complete ‘web’ brings out
unique features of each ligands’ efficacy. For example, while
the ligands nebivolol and SR59230A have identical efficacy
for elevation of levels of activator protein-1 (AP-1), they yield
completely different efficacies for altering levels of NF-kB and
cAMP (Evans et al., 2010). Such variation also will likely be
seen in response systems where multiple stimuli converge to
yield a total outcome (i.e. whole cell response). In view of the
increasing prevalence of label free assay systems (Kenakin,
2009a; Fang, 2010a,b; Schröder et al., 2010), it would be pre-
dicted that label free agonist potency ratios will vary with cell
type and other conditions. Furthermore, not considered in
these discussions is the influence of real-time kinetics (Sykes
et al., 2009; Guo et al., 2012) and the impact of pathophysi-
ology on cell signalling mechanisms. These effects may well
influence label-free responses in primary cell systems.
The loss of uniformity of whole cell agonist potency ratios
poses a problem for drug discovery since agonists usually are
optimized in test systems for use in therapeutic ones. In
monotonic stimulus–response systems, agonist potency
ratios allow prediction of relative agonist activity in any
system. However, in systems where biased agonism is
encountered, cell-based relative potencies may not provide
system-independent measures of agonism. Since these are
required for successful drug discovery, this raises the ques-
tion how can biased efficacy be quantified in a system-
independent manner?
Quantification of biased efficacy
For calculation of agonist activity ratios, a single number for
each agonist is optimal. For full agonists producing the
system maximal response, ratios of EC50 values (the effective
concentration producing 50% of the maximal response to the
agonist) are adequate as a single number since the maximal
responses for two agonists will not be an issue. However, in
general, agonism is characterized by a maximal response and
a potency; therefore, the maximal response must be consid-
ered for partial agonists. EC50 values become ambiguous as
single descriptors of agonism for two agonists of differing
maximal response. For instance, a greater response will be
observed from a concentration of 10 nM of an agonist of
pEC50 8.0 and maximum of 90% than one with a pEC50 of 9.0
and a maximum of 15%, yet the ratio of EC50 values would
indicate otherwise. Thus, both affinity and efficacy must be
considered for a single number of agonism to be of value.
This problem is solved for dose–response curves of unit slope
with the application of relative activity (RA) ratios. Proposed
by Ehlert and colleagues (Ehlert, 2005; Figueroa et al., 2009;
Tran et al., 2009), the RA value is the maximal response of the
agonist divided by the EC50. This furnishes a single number
reflecting the power of a molecule to produce agonism in any
system.
The value of ratios of agonism such as relative RA values
is that they can be determined in a test system for prediction
of relative agonism in the therapeutic one; that is, they
should be transferrable across systems. Ignoring the problem
of non-monotonic stimulus–response coupling for the
Figure 5
Effects of varying receptor/coupling protein stoichiometry on relative agonist activity. The receptor mediates cellular response through activation
of two effectors 1 and 2. Agonist A produces a relatively uniform activation of both response effectors, whereas agonist B is biased towards
effector-2. In cells with an increased stoichiometric ratio of receptor to effector 2, the response to agonist B will be disporportionateloy augmented
to yield a different relative potency ratio for the two agonists in the two systems.
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moment, an analysis of RA ratios, in terms of the Black/Leff
operational model, shows how relative RA ratios are transfer-
rable across systems in cases where the slope of the dose–
response curve is unity. Thus the Black/Leff operational
















where Em represents the maximal response capability of the
system, KA is the equilibrium dissociation constant of the
agonist–receptor complex, n is the slope of the dose–response
curve and t is the efficacy. This final term represents the
receptor density and molecular interaction of the agonist–
receptor complex interaction with the stimulus–response
system of the cell, which itself has ligand-specific elements
(efficacy of the ligand) and system-specific elements (effi-
ciency of coupling of receptors to signalling pathway).
A theoretically complete term to describe the power of a
ligand to active a cellular pathway is the term t/KA; this
incorporates both elements of efficacy and affinity. Consid-
ering that the most common difference between systems is
receptor density, ratios of t/KA account for these and should
be system-independent measures of the relative power of
ligands to activate pathways. In fact, it has been shown
experimentally that t/KA values for muscarinic agonists do
not change with a change in receptor density (Kenakin et al.,
2012). In terms of the maximal response and EC50 for dose–
response curves in the Black Leff operational model (see Black

















For dose–response curves of unit slope (n = 1), it can be seen
that RA reduces to the term Em(t/KA). Ratios of these terms for
particular agonists cancel the Em term and are therefore system
independent. However, when n  1, equation 6 shows that RA
values become system dependent (and therefore less useful as
universal descriptors of agonism). For this reason, in these
cases, the direct fitting of data to the Black/Leff operational
model (equation 5) and estimation of t/KA values is a theoreti-
cally more sound method of reducing agonism to a single
index (Kenakin, 2009b; Kenakin and Miller, 2010; Evans et al.,
2011; Tschammer et al., 2011; Kenakin et al., 2012). Values of
t/KA have the added advantage of circumventing another issue
with full agonists, namely the fact that an infinite variety of
combinations of efficacy and affinity can describe any given
curve to a full agonist (there is no unique value of efficacy that
can be identified unless the curve indicates partial agonism). It
has been shown that the potency of an agonist can be
described by the Black/Leff model as (Black et al., 1985):
EC A50 12 1
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Systems where cell type (A), receptor/G-protein stoichiometry (B) or assay technology (C) produce variability in agonist potency ratios





(hCalcitonin R) DPR (COS to CHO) Reference
pCal 1 1 1 Christmanson et al.,
1994hCal 2.6 ¥ 10-3 0.1 38.5
hCGRP 1.48 ¥ 10-5 0.024 1621




(hCalcitonin R) DPR (HEK to HEKGas)
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ECal 3.53 0.17 20.8












aCellular dielectric spectroscopy (Cell Key).
pCAL, porcine calcitonin; Ecal, Eel calcitonin; hCal, human calcitonin; hCGRP, calcitonin gene related peptide; 7OH-DPAT, 7-hydroxy-N,N-
dipropyl aminotetralin.
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Therefore, for high-efficacy full agonists (as t values get large),
a limiting value for KA is the EC50 (i.e. a first approximation
for curve fitting would be to set KA to values >EC50). Subse-
quent iteration then identifies a unique ratio t/KA that char-
acterizes the full agonist response.
A very similar method for the quantification of ligand bias
has been published, which yields a factor lig that is essen-
tially a t value for a given signalling pathway (Rajagopal et al.,
2011). This method relies on an independent estimate for KA.
Theoretically this can be obtained from binding experiments
however a major shortcoming of this approach is that allos-
teric binding affinity is dependent upon the nature of the
co-binding ligand. Specifically, it can be shown that the con-
centration of ligand–receptor complex (expressed as a frac-
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where [A] is the co-binding ligand; KB and KA refer to the
equilibrium dissociation constants of the allosteric and
co-binding ligand, respectively; and a is the co-operativity
factor for affinity between the allosteric and co-binding
ligand. The observed (and operative) affinity, which will be
the reciprocal of KB(oper.) of the allosteric ligand (for opera-
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It can be seen from equation 9 that if the co-binding ligand
does not impose cooperativity on the allosteric ligand (i.e. if
a = 1), then the operational affinity will equal KB, and it will
be system independent. However, if a  1, then the affinity of
the allosteric ligand (the 7TMR agonist) necessarily will
depend on both the nature of the co-binding ligand (a)
and its concentration. For example, the operational affinity
of the NMDA receptor antagonist ifenprodil changes by a
factor of 5.17 when the concentration of the co-binding
ligand (in this case, NMDA) is increased by a factor of 10 (Kew
et al., 1996). Similarly, binding studies with the allosteric
ligand [3H]dimethyl-W84 (N,N-bis[3-(1,3-dihydro-1,3-dioxo-
4-methyl-2H-isoindol-2-yl)propyl]-N,N,N′,N′-tetramethyl-1,
6-hexanediaminium diiodide) show that the affinity of the
allosteric ligand gallamine for the free muscarinic M2 recep-
tor is pKi = 8.27  0.39, while in the presence of 1 mM of the
co-binding N-methylscopolamine, it changes by a factor of 47
to pKi = 6.6  0.19 (Trankle et al., 1999).
It is well known that signalling proteins co-binding to
receptors produce changes in the affinity of agonist ligands.
For example, peptide fusion experiments in Sf9 membranes
show a 27-fold (b2AR Ki = 116 nM; b2AR-Gas fusion Ki =
4.3 nM) increased affinity for isoproterenol with the presence
of nucleotide-free Gs heterorimer protein to b2-adrenoceptors
(Rasmussen et al., 2011). Studies utilizing the substituted
cysteine accessibility method (SCAM) with k-opioid receptors
have shown clear changes in receptor conformation in trans-
membrane domains 6 and 7 with binding of Ga16 and/or Gai2
G-protein subunits. These changes in conformation lead to
substantial changes in the binding affinity for k-opioid
ligands (e.g. salvanorin shows an 18-fold change in affinity)
(Yan et al., 2008). Recent studies on ghrelin receptors recon-
stituted into lipid discs labelled with a fluorescent reporter
show clear presence of different receptor conformations upon
addition of Gq to nanodiscs. Similarly, double exponential
fluorescent lifetime decay analysis indicates the creation of
yet different conformations upon addition of b-arrestin in the
presence of ghrelin (Mary et al., 2012).
For 7TMR agonists, the ‘co-binding ligand’ is the signal-
ling coupling protein. Therefore, there is no basis to believe
that KA estimates made in binding will have any relevance to
the KA for the specific signalling molecule (guest) in the cell
for a given pathway. The operational affinity for the specific
pathway must be used to adequately estimate the correct t
value for activation of that pathway. Through utilization of
an operational KA obtained through fitting the functional
data, the t value is scaled to a unique value when Log(t/KA)
(or Log(RA) values for systems where the slope of dose–
response curves is not significantly different from unity) esti-
mates are used. The use of lig ratios is formally identical to
Log(t/KA) values if the true pathway KA is known (and not
simply obtained through binding). If a uniform estimate of
affinity (or an estimate from binding studies is) is used to
calculate lig values, it can be shown that an error will result
equal to the difference in the affinities of the agonist for




























where KA-Apath1 and KA-Apath2 refer to the relative affinity values
for an agonist A for 2 pathways path1 and path2, and KA-Bpath1
and KA-Bpath2 refer to the relative affinity values for an agonist
B for 2 pathways path1 and path2. A summary of some
simple methods to quantify agonist bias is given in Table 2.
Receptor occupancy and efficacy-
driven phosphorylation barcodes
While biased signalling usually is discussed in terms of active
trafficking of cellular stimulus to various pathways, there are
two other aspects of biased effects that can contribute signifi-
cantly to overall selective ligand profiles in vivo; these are (1)
the physical occupancy of the endogenous ligand binding
site by the biased ligand and (2) the pattern of phosphoryla-
Table 2








2 Full agonists √ √ √
1 Full + 1 Partial
Agonist (n = 1)a
X √ √
1 Full + 1 Partial
Agonist (n  1)a
X X √
aHill coefficient of the dose–response curve.
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tion of the receptor by cellular kinases controlled by the
ligand-specific conformation. In terms of receptor occupancy,
it should be recognized that a biased ‘agonist’ will function as
an antagonist of endogenous molecules. Thus, the biased
b-arrestin angiotensin molecule SII prevents angiotensin-
mediated G-protein activation through angiotensin II recep-
tors by its presence on the receptor. In addition, SII activates
b-arrestin pathways; therefore, in this sense, SII could also be
seen as a ‘biased antagonist’. As predicted for SII, the receptor
antagonism by biased ligands may be an important aspect of
the overall therapeutic value of biased ligands through dimi-
nution of angiotensin-induced activation of G-protein path-
ways that lead to a debilitating vasoconstriction in heart
failure. Another such biased ‘agonist-antagonist’ is the hista-
mine H4 antagonist JNJ7777120 (1-[(5-chloro-1H-indol-2-yl)
carbonyl]-4-methylpiperazine); this ligand blocks G-protein-
mediated signalling ([35S]GTPgS binding) but actively
promotes histamine receptor recruitment of b-arrestin
(Rosethorne and Charlton, 2011). Another example of where
this type of profile of activity may yield therapeutic benefit is
with the dopamine D2 receptor b-arrestin biased agonist
UNC9975 (7-(4-(4-(2,3-dichlorophenyl)-1,4-diazepan-1-yl)
butoxy)-3,4-dihydro-1,8-naphthyridin-2(1H)-one). This mol-
ecule is a partial agonist that blocks the Gi-protein-mediated
cAMP of dopamine. It has been shown that this unique
profile of b-arrestin agonism and Gi-protein antagonism leads
to responses predicting antipsychotic activity in inbred
C57B/6 mice in vivo without induction of debilitating motor
side effects (Allen et al., 2011).
There are functions of receptors that appear to require a
memory of past signalling events (i.e. desensitization with or
without internalization, recycling to the cell surface versus
degradation of receptors, etc.). There are numerous lines of
evidence to implicate specific receptor phosphorylation in
the coding of receptor function after ligand binding (for
reviews see Tobin, 2008; Tobin et al., 2008). Advances in
biochemical technology of protein phosphorylation (i.e.
tryptic phosphopeptide maps, phosphor-specific antibodies,
mass spectrometry) (Butcher et al., 2011; Kelly, 2011) have
allowed the demonstration of agonist-selective direct phos-
phorylation of receptor states. For example, the m-opioid
receptor agonists DAMGO and etonitazene stimulate the
phosphorylation of both Thr370 and Ser375, whereas morphine
leads to phosphorylation of only Thr370 (Doll et al., 2011).
These patterns of phosphorylation ‘barcode’ receptor for
future disposition within the cytosol (Butcher et al., 2011;
Nobles et al., 2011). In general, agonist functional selectivity
in vivo should be considered a combined effect of unique
efficacy due to stabilization of receptor conformations (stimu-
lus bias and receptor phosphorylation) and antagonism due
to receptor occupancy (see Figure 6).
Therapeutic application of
signalling bias
There are an increasing number of examples of the successful
development of biased agonists and antagonists; what pres-
Figure 6
General view of three mechanisms for agonist selectivity in vivo. Thus, stabilization of unique receptor conformations can lead to bias of interaction
of the receptor with cellular signalling molecules (stimulus trafficking) and presentation of conformations to GRKs for selective barcoding through
phosphorylation. Binding of the agonist to the receptor interferes with the interaction of the receptor with the endogenous agonist.
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ently is still not clear is the therapeutic significance of these
new molecules. One of the main questions to be answered is
how in vitro profiles of signalling bias will translate to in vivo
conditions. It is evident that in a defined cell type (with set
receptor density, relative stoichiometry of signalling elements
and set efficiencies of receptor coupling), quantitative differ-
ences in cellular signals can be produced by different agonists
(i.e. agonist-specific signalling profiles). However, the agonist
will interact with a wide range of systems of varying receptor
density. In addition, the concentration of agonist in vivo will
be a changing quantity as the ligand is absorbed and cleared
in vivo. Both of these effects can lead to varying ranges of
signalling bias in the body with time. Figure 7 shows two
agonists with a defined bias towards two signalling pathways;
specifically, agonist A has high affinity and efficacy for both
pathways, while agonist B has a high affinity but low efficacy
for pathway 2 (over pathway 1). It can be seen from the bias
plot (which simply expresses the response for pathway 2 for
a given response for pathway 1) that agonist B reverses its
relative bias over a concentration range. In general, as ago-
nists are exposed to a range of cell types and change their
relative concentration in vivo, it will be predicted that the
overall signalling patterns produced will be extremely
complex. This can be demonstrated further by calculating
relative bias for agonists in a range of tissues with changing
receptor densities. Figure 8 shows the signal produced by a
biased agonist in a range of tissues of differing receptor
density. In this case, the overall signal is taken to be the
arithmetic difference of the two signalling pathways
(obtained from the individual dose–response curves for each
receptor system as the dotted and solid lines in Figure 8), but
the nature of the forcing function uniting the various path-
ways into a whole cellular response is immaterial to the
prediction. In general, it can be seen that the signals can vary
dramatically over ranges of concentration and tissue types.
Differences in receptor density have been shown to affect
the predominance of agonism in signalling pathways. For
example, in CHO cells containing high and low levels of
expression of b3-adrenoceptors, the dominant signalling
pathways changes from cAMP to p38 MAPK; and this, in turn,
leads to differences in the bias of the ligands CL316243
((R,R) -5- [2- [[2- (3-chlorophenyl) -2-hydroxyethyl] -amino]-
propyl]1,3-benzodioxole-2,2-decarboxylate) and SR59230A
(3- (2-ethylphenoxy)-1- [(1,S) -1,2,3,4- tetrahydronapth-1-
ylamino]-2S-2-propanol oxalate) (Sato et al., 2007). In practi-
cal terms, the difficulty in predicting in vivo bias necessitates
testing exemplar agonists (extremes of bias as determined in
vitro) in the therapeutic system as early as possible in the
discovery and development process.
Efficacy as a receptor property
The discovery that receptors can spontaneously form an
active state that leads to constitutive cellular activity neces-
sitates the notion that the receptor itself must have efficacy.
This would be defined as the difference in the receptor behav-
iour towards the cell when it spontaneously forms an active
state from cell activity with receptors present in the inactive
state. The magnitude of receptor efficacy would be related to
the allosteric constant controlling the spontaneous ability of
the receptor to form the active state (allosteric constant = L =
Figure 7
Bias plot for two agonists: A (relatively equal efficacy for pathways 1 and 2) and agonist B (higher affinity but lower efficacy for response 2). Panels
on the right show the dose–response curves for both agonists for the two signalling pathways. The bias plot shows the response of each agonist
for pathway 2 as a function of the response for pathway 1. For this particular tissue, agonist A produces relatively uniform activation of both
pathways, while agonist B produces a selective effect for pathway 2 at low levels of stimulation followed by a saturated and lower level of response
2 at higher stimulation levels. Thus, bias is concentration and system dependent in that low concentrations of agonist B are biased 2 > 1, while
higher concentrations the bias is reversed.
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[Ra]/[Ri], where [Ra] and [Ri] refer to the concentrations of the
active and inactive states respectively). Through transient
transfection of receptors, it has been shown that receptors
have varying propensity to produce constitutive activity (i.e.
form the active state) (Fathy et al., 1999; Chen et al., 2000;
Leeb-Lundberg et al., 2001). The ability of the spontaneously
formed active state conformation to interact with cellular
signalling proteins defines the relative cellular signalling ‘effi-
cacies’ of this spontaneous active state. It already has been
noted that there are data to indicate that the spontaneously
formed active state(s) of the b2-adrenoceptor (Zhou et al.,
1999) and the m-opioid receptor (Liu et al., 2001; Doll et al.,
2011; Lau et al., 2011) differ in their signalling characteristics
from their agonist-bound counterparts. The efficacy of the
intrinsic receptor will be related its amino acid sequence and
tertiary structure. An extreme example of this variation is the
activity of DREADDs (designer receptors exclusively activated
by designer drugs, also referred to as RASSLs, receptors acti-
vated solely by synthetic ligands); these are engineered recep-
tors that, by virtue of their structure, have lost their ability to
be activated by natural agonists but are activated by synthetic
agonists (Conklin et al., 2008; Pei et al., 2008; Dong et al.,
2010; AlvarezCurto et al., 2011).
There is no reason a priori to assume that the spontaneous
receptor active state will not have a bias in its own right that
differs from the ligand-bound signalling bias. For example, it
has been shown that post-transcriptional mRNA editing can
produce mutations of the 5-HT2C receptor, and that these
edits differentially alter ligand-dependent and independent
signalling (Berg et al., 2008). This suggests that the very same
strategies and tools used to quantify receptor bias can be used
to do the same for mutant receptors. An example of how
receptor mutation can produce quantifiable differences in
ligand bias can be seen in the dopamine D2L receptor (Tsc-
hammer et al., 2011). As shown in Table 3, the relative bias of
seven dopamine agonists for cAMP versus ERK1/2 signalling
seen in the wild-type receptor differs considerably from the
bias of these agonists in a mutant counterpart (H3936.55A).
This bias signature indicates a basic change in the signalling
properties of the protein upon mutation of His3936.55 to
alanine (Tschammer et al., 2011).
Conferring efficacy to receptor states is a useful concept
when considering ionic effects on receptors. For example,
functional effects are observed with the orphan receptor
GPR39 with Zn2+. As described by Storjohann et al. (2008), the
effect of ions such as Zn2+ can be described as the stabilization
of a constitutively active receptor state. Seen within this
context, ionic stabilization of receptor states is formally
similar to receptor mutation and can be described in terms of
efficacy.
Linking efficacy to drug labels
Traditionally, pharmacology has actively been involved in
the taxonomy of biologically active molecules (i.e. the clas-
sification and naming of drugs). These classifications have
been linked with efficacy. Historically, this was a fairly simple
Figure 8
Relative agonist response (calculated as the arithmetic difference of pathway stimulations indicated by dotted and solid dose–response curves in
separate panels) for a wide range of tissues of differing receptor density. At low receptor density, the agonist produces primarily response denoted
by the dotted dose–response curve, while at high receptor densities, a more balanced stimulation is obtained. The surface shows the complexity
of overall stimulation to the range of systems with varying receptor densities.
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procedure involving the target (receptor type and subtype)
and most prominent observed effect (agonist, antagonist).
However, as the number of vantage points available to view
receptor behaviour increases, so too does the list of observed
pharmacological actions, and these often lead to a plethora of
conflicting labels (Kenakin, 2008). For example, the CB1 can-
nabinoid ligand desacetyllevonantradol is a positive agonist
for Gi1 and Gi2 but an inverse agonist for Gi3. Similarly, (R)-
methanandamide is an inverse agonist for Gi1 and Gi2 but a
positive agonist for Gi3 (Mukhopadhyay and Howlett, 2005).
As discussed previously, drugs can even change their classifi-
cations with cellular conditions as in the case of protean
agonists. Thus, the b-adrenoceptor protean agonist dichlor-
oisoproterenol can produce partial agonism in some systems
and inverse agonism in others (Chidiac et al., 1996). Simple
labels based on single efficacies of ligands can become
obstructive to the understanding of valuable therapeutic phe-
notypes. For example, the constellation of efficacies belong-
ing to carvedilol (beyond its activity as a b-blocker) may be its
most important feature as a treatment for congestive heart
failure (Metra et al., 2004). These ideas suggest that as pluri-
dimensional efficacies are identified for drugs, classifications
and labels for drugs must be adjusted accordingly. This com-
plicates the future for nomenclature compendia, such as the
Guide to Receptors and Channels (Alexander et al., 2011) and
GuideToPharmacology.org.
Conclusions
The simple concept of efficacy as a measure of the power of an
agonist to produce cellular activation through a 7TM receptor
has undergone radical modification over the past 20 to 25
years. These changes have both opened new therapeutic hori-
zons for 7TMR drugs and also made the process of discovering
and developing these new therapies more challenging. These
new ideas related to efficacy have changed pharmacological
approaches to new drug discovery in specific ways to indicate
the following concepts:
• Simple cell-based potency ratios may not be suffi-
cient for prediction of therapeutic agonism in all
systems.
• Efficacy has quality as well as quantity in that textured
and non-uniform signalling may be produced by synthetic
agonists.
• ‘Hits’ from screens should not be assumed to produce equal
quality of response.
• Efficacy is pluridimensional, and it may be the complete set
of efficacies for any given compound that contribute to its
overall therapeutic value.
• Pharmacological assays are the key to observing unique
efficacy patterns.
Table 3
Agonist Bias for the wild-type Dopamine D2L receptor versus its H3936.55A mutant counterpart
(A) D2L wild-type receptor
cAMP Log(t/KA) cAMP Dlog(t/KA) ERK1/2 Log(t/KA) ERK1/2 Dlog(t/KA) BIAS DDLog(t/KA)
Quinpirole 8.68 0 8.41 0 0
7-OH-DPAT 8.73 0.05 9.17 0.76 -0.71
Dopamine 8.7 0.02 8.62 0.21 -0.19
Aripiprazole 7.16 -1.52 6.67 -1.74 0.22
FAUC335 7.13 -1.55 7.29 -1.12 -0.43
FAUC321 7.7 -0.98 8.19 0.22 -1.2
FAUC346 6.18 -2.5 5.91 -2.5 0
(B) D2L H2936.55 A receptor
cAMP Log(t/KA) cAMP Dlog(t/KA) ERK1/2 Log(t/KA) ERK1/2 Dlog(t/KA) BIAS (DDLog(t/KA)
Quinpirole 6.69 0 7.36 0 0
7-OH-DPAT 7.55 0.86 7.71 0.35 0.51
Dopamine 6.75 0.06 6.45 -0.91 0.97
Aripiprazole 6.25 -0.44 6.91 -0.45 0.01
FAUC335 7.06 0.38 7.53 0.17 0.21
FAUC321 7.78 1.09 8.26 0.9 0.19
FAUC346 6.96 0.27 7.48 0.12 0.15
DLog(t/KA) values taken with Quinpirole as the reference standard agonist. Bias values represent the relative activation of the cAMP pathway
versus the ERK1/2 pathway (DDLog(t/KA)).
FAUC335 = N-[3-[4-(2-methylsulfanylphenyl)piperazin-1-yl]propyl] pyrazolo-[1,5-a]pyridine-3-carboxamide.
FAUC321 = N-[3-[4-(2-methoxyphenyl)piperazin-1-yl]pyrazolo-[1,5-a] pyridine-3-carboxamide.
FAUC346 = N-[4-[4-(2-methoxyphenyl)piperazin-1-yl]butyl] benzo[b]thiophene -2-carboxamide.
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Finally, at this point in time, there are compounds in late
stage development that may allow the translational process
of relating biased efficacy to therapeutic phenotypes.
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